Form 4: Agenus Inc. CEO Garo Armen Receives Stock in Lieu of Cash Salary

Agenus Inc. CEO Garo Armen received 6,332 shares of common stock as payment for his salary for the pay period ending March 7, 2025, while also disposing of 148,383 shares.

Summary

• On March 7, 2025, Garo H. Armen, CEO of Agenus Inc., acquired 6,332 shares of Agenus Inc. common stock at a price of $2.35 per share as part of his salary compensation.
• This was in lieu of a cash payment, as approved by the Agenus Inc. Compensation Committee.
• The shares were issued according to the Amended and Restated Agenus Inc. 2019 Equity Incentive and are fully vested upon issuance.
• Armen also disposed of 148,383 shares.
• Following the transaction, Armen directly owns 148,383 shares, indirectly owns 31,298 shares through IRA accounts, and indirectly owns 28,950 shares as trustee and general partner.

Sentiment

Score: 5

Explanation: Neutral sentiment. The stock acquisition as salary is a positive sign of alignment, but the disposal of shares could raise concerns.

Positives

• The CEO accepting stock in lieu of cash may signal confidence in the company's future performance.

Negatives

• The disposal of 148,383 shares by Armen could be interpreted negatively by investors.

Risks

• The market's reaction to the CEO's stock transactions could be volatile.
• The company's reliance on equity-based compensation may dilute existing shareholders.

Management Comments

• Garo H. Armen's salary is being paid in stock, in lieu of cash, at his request and with the approval of the Agenus Inc. Compensation Committee.

Industry Context

This type of equity compensation is common in the biotech industry, especially for companies looking to conserve cash. It aligns management's interests with shareholders.

Comparison to Industry Standards

• Equity compensation is a common practice among biotech companies, particularly those in the development stage, such as Agenus.
• Comparing Agenus's equity compensation practices to companies like Juno Therapeutics (acquired by Celgene) or Kite Pharma (acquired by Gilead) during their early stages could provide a benchmark.
• These companies also utilized stock options and grants to attract and retain talent while managing cash flow.

Stakeholder Impact

• Shareholders may be impacted by potential dilution from stock-based compensation.
• Employees may view the CEO's acceptance of stock as a positive sign of confidence in the company.

Key Dates